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ABSTRACT
Endothelial cell-specific molecule-1 (ESM-1), also known as endocan, is a soluble proteoglycan expressed
by the vascular endothelium, which also circulates in the bloodstream. Inflammatory cytokines and proangiogenic growth factors increase its expression, and increased serum levels have been reported in several
cancer types and immunocompetent patients with sepsis. The aim of this study was to analyze the expression
profile of CXC-chemokines and the effects of ESM-1 gene knockdown in proliferation, migration and CXCchemokine expression in highly metastatic human prostate PC-3 cells. Expression profiles of CXC-chemokines were analyzed in metastatic PC-3 and non-tumorigenic PWR-1E cells. siRNA-mediated knockdown of
ESM-1 was performed into PC-3 cells, which were subsequently tested for cell migration and proliferation.
Effect of siRNA transfection on CXC-chemokine expression was further quantified at the transcript and protein level. RT-qPCR analysis and sandwich ELISA assay revealed higher levels of ESM-1 and several CXCchemokines in metastatic PC-3 cells compared to non-tumorigenic PWR-1E. Transfection of PC-3 cells with
ESM-1-siRNA decreased cell migration with no effect on proliferation, and it was accompanied by decrease
in the transcript and protein levels of the angiogenic chemokine CXCL3. We report here for the first time the
ESM-1 targeting in PC-3 cells, which resulted in decreased migration, which may be related, at least in part,
to decreased expression of the angiogenic CXCL3 chemokine, whose expression was found to be reduced in
ESM-1-siRNA transfected cells. Additional studies are required to ascertain the biological role of ESM-1 in
prostate cancer cells and the link with the expression of CXCL3. (Int J Biomed Sci 2017; 13 (1): 35-42)
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INTRODUCTION
Endothelial cell-specific molecule-1 (ESM-1), also
known as endocan, is a secreted proteoglycan whose transcripts were initially detected from a variety of cultured
human endothelial cells of different origins, including
coronary, pulmonary artery, dermal, and capillary endothelial cells (1, 2). More recent studies have reported its
expression by epithelial tumor cells and cancer cell lines,
such as prostate cancer cells (3, 4), melanoma cells (5, 6),
and glioblastoma cell lines(7). It has been found also in the
blood circulation of healthy subjects (8), and increased levels have been reported in patients with different pathologies, including inflammatory bowel disease (9), hepatocellular carcinoma (10), acute myeloid leukemia (11), among
others.
ESM-1 is regarded as a marker of angiogenesis, an important factor in the progression of cancer (12). Its transcriptional expression has been shown to be regulated by
angiogenic growth factors, such as vascular endothelial
growth factor (VEGF), and by inflammatory cytokines,
such as tumor necrosis factor alpha (TNF-α) (13).
Angiogenesis is a process shown to be regulated by
different factors, produced by both tumor cells and host
responding cells (14). Among the regulatory factors, increasing evidence supports the important role of CXC
chemokines in the process of angiogenesis (15, 16). The
majority of CXC chemokines contain at the NH2 terminus
a three-amino-acid motif (Glu-Leu-Arg: the ELR motif),
which precedes the first cysteine amino acid of the primary structure of these cytokines (17). The CXC chemokine
family members that contain the ELR motif (ELR+) are
potent promoters of angiogenesis (18), while members that
lack the ELR motif (ELR−) are potent inhibitors of angiogenesis, or angiostatic (18, 19).
We have previously reported the over-expression of
ESM-1 in prostate cancer cell lines from rat (3) and human origin (4). The aim of this work was to analyze the
expression profile of CXC-chemokines and the effects of
ESM-1 gene knockdown in proliferation, migration and
CXC-chemokine expression in highly metastatic human
prostate PC-3 cells.

MATERIALS AND METHODS
Cultured cell lines
Human bone metastasis-derived prostate cancer PC-3
cells (ATCC® CRL-1435) and non-tumorigenic human
prostatic epithelial PWR-1E cells (CRL-11611) were ob-
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tained from the ATCC (Manassas, VA). PC-3 cells were
routinely maintained in phenol red-positive F-12K modified medium (ATCC) containing 10% FBS and 1% penicillin-streptomycin. PWR-1E cells were maintained in
keratinocyte serum-free medium (Life Technologies)
supplemented with 50 μg/mL bovine pituitary extract, 5%
L-glutamine, and 5 ng/mL epidermal growth factor. Cells
were grown as monolayers in T-25 tissue culture flasks,
in a humidified atmosphere containing 5% CO2 at 37°C
and passaged once/twice a week. For all the experiments,
cells were harvested at low passage numbers: PC-3 cells
between passages 28 and 31, and PWR-1E between passages 18 and 22.
siRNA-mediated knockdown of ESM-1 gene expression
Small interfering RNA targeting the ESM-1 gene
(siESM-1) and scramble siRNA sequence (siControl),
were purchased from Qiagen (FlexiTube GeneSolution
GS11082 for ESM-1). PC-3 cells were seeded into 12-well
cell culture plates (Corning®) and incubated for 24 h in
Opti-MEM® reduced serum medium (GIBCO) without
FBS. Then, cells were subjected to transfection with either siESM-1 or siControl using the RNAi Human/Mouse
Starter Kit (Qiagen) following the manufacturer’s instructions. Briefly, 300,000 cells were mixed with siRNAs solution complexed with the transfection reagent, and the
mixture was incubated at normal culture conditions for 48
hours. Non-transfected (NT) cells treated in the same way
were used as control.
Cell viability and proliferation assays
To measure the cell survival and proliferation rate of
PC-3 cells, after treatment with siESM-1 or siControl, cell
viability and proliferation were analyzed 48 h post-transfection using two methods: a direct cell counting using trypan blue dye exclusion and a colorimetric MTS-based cell
viability kit (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega®). For trypan blue dye exclusion
method, PC-3 cells transfected with siRNAs were mixed
with 10 ul trypan blue (0.4% in PBS) and the number of
viable, unstained cells, was determined using a Neubauer
chamber. For the MTS-based assay, PC-3 cells transfected
with siRNAs were mixed with 20 μL CellTiter solution
(Promega) and incubated for an additional 4 h at 37°C.
Then, absorbance was measured at 490 nm in a Multiskan
FC microplate reader (Thermo Scientific). MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt] is a tetrazolium
salt that is reduced to water-soluble formazan mainly by
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mitochondrial dehydrogenase enzymes found in metabolically active cells. The quantity of formazan product as
measured by the amount of 490nm absorbance is directly
proportional to the number of living cells in culture (20).
Scratch assay for analysis of cell migration in vitro
To evaluate the effect of ESM-1 gene expression knockdown in cell migration, the scratch assay was performed
(21). PC-3 cells were seeded onto 6-well plates at density
of 3 × 106 cells/well, and incubated at 5% CO2 and 37oC for
24 h. Then, cells were transfected with ESM-1-siRNA or
control-siRNA, and incubated for additional 24h. Media
was subsequently replaced by serum-free Opti-MEM and
cells were incubated until they reached 90-100% confluence. At this point, a vertical scratch was performed on
PC-3 cells monolayer using a sterile 1,000 μl micropipette
tip. Cells were carefully washed with Opti-MEM to remove scratched cells, and further incubated at 37°C in fresh
Opti-MEM. Wound closure was monitored every 12 h post
scratch with a trinocular inverted microscope (Motic AE31).
Images were analyzed with the TScratch software (22). Experiments were performed in triplicates. Untransfected and
control-siRNA transfected cells were used as controls.
Total RNA extraction and quality control
Untransfected PWR-1E cells were used as the reference cell line for comparison of gene expression between
transfected and untransfected conditions. To analyze the
effects of siRNA transfection in gene expression, controlsiRNA transfected PC-3 cells were used as control. Total RNA was isolated from PC-3 cells on the following
conditions: untransfected, ESM-1-siRNA transfected, and
control-siRNA transfected. RNA isolation was performed
with TRI-Reagent (Ambion), following the manufacturer’s instructions. The concentration and purity of the
extracted total RNA was assessed spectrophotometrically
by measuring OD260 and OD260/280 ratio respectively in
RNase-free H2O using Nanodrop 2000c (Thermo Scientific). Three replicates of each RNA sample were measured
and the measured concentrations were averaged. For all
samples OD260/280 ratio was ~2.0. Total RNA samples
were stored at −80°C until used.
cDNA synthesis and reverse transcription quantitative
real-time PCR (RT-qPCR)
RNA samples from cell lines were processed for reverse
transcription using the QuantiTect Reverse Transcriptase
kit (Qiagen). First, to eliminate any contaminating genomic
DNA, 1μg of total RNA was incubated with genomic DNA
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Wipeout Buffer (Qiagen) for 2min at 42°C. The reversetranscription master mix, containing QuantiTect RT enzyme, QuantiTect RT Buffer and RT Primer Mix (oligo-dT
and random primers), was prepared and added to the template RNA. Samples were incubated at 42°C for 15 min,
followed by inactivation at 95°C for 3 min. A 20 μL final
volume of cDNA was stored at −20°C until used in qPCR.
Transcript expression levels for ESM-1, ELR+ CXC
chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6,
CXCL7, and CXCL8), ELR− CXC chemokines (CXCL4,
CXCL9, CXCL10, CXCL11, CXCL12, and CXCL14), and
reference genes HPRT-1 and β-actin were analyzed in the
cell lines by qPCR using QuantiTect SYBR Green PCR
Master Mix (Qiagen). Primers specific for ESM-1 and the
reference genes HPRT-1 and β-actin were designed with
Primer-BLAST (23) using sequences from GenBank database. All primers were designed to span at least one exon–
intron boundary to avoid detection of residual genomic
DNA. For gene expression analysis of CXC-chemokines,
Chemokines qSTAR qPCR primer panels (HPP6004A)
were purchased from OriGene Technologies (Rockville,
MD). qPCR reactions for each sample were carried out in
triplicates, using QuantiTect® SYBR® Green PCR Master
Mix (Qiagen) in a StepOne thermocycler (Applied Biosystems), with an initial denaturing step at 95ºC for 15 min,
followed by 40 cycles of amplification of 95 °C for 15 s,
55 °C for 45 s and 60°C for 1 s. Negative controls (nontemplate control and negative reverse transcriptase control)
were also included. Relative changes in gene expression
for each target gene in the cell lines were calculated with
the Sequence Detection System 2.1 software (Applied
Biosystems), using the comparative CT method (2–ΔΔCT).
Expression levels for each target gene were normalized to
the expression levels of the reference genes HPRT1 and
β-Actin. Melting curves for all samples were acquired for
quality control purposes.
Enzyme-linked immunosorbent assay for CXC Chemokine measure
Supernatants were collected from cells cultured in
serum free medium for 48 hours. Cell supernatants were
cleared by centrifugation at 13,000 rpm for 5 min. Protein
level for each chemokine was measured by quantitative
enzyme-linked immunosorbent assay (ELISA). CXCL1/
GROα, CXCL8/IL8, CXCL9/MIG, CXCL10/ IP-10, and
CXCL11/I-TAC protein levels were determined using the
Human Common Chemokines Multi-Analyte ELISArray
Kit (SABiosciences, Qiagen, Valencia, CA, USA), while
CXCL3 protein level was determined with a single ELISA
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assay kit (Cat #: MBS910472, Mybiosource, San Diego,
CA, USA). Briefly, 50 µL of medium was incubated in a
96-well plate for 1 hour at RT, followed by washing steps,
incubation with detection antibodies for 1 hour, washing, incubation with avidin-horseradish peroxidase for 30
minutes, washing, development for 15 to 30 minutes, and
termination of the development with stop solution. Chemokine protein levels were measured on a MultiSkan microplate reader (Thermo) with an absorbance at 450 nm.
Sampling was performed in triplicates.
Enzyme-linked immunosorbent assay for ESM-1 measure
Supernatants were collected from cells cultured in
serum free medium for 48 hours. Cell supernatants were
cleared by centrifugation at 13,000 rpm for 5 min. ESM-1
protein levels were measured using a commercial enzymelinked immunosorbent assay (Aviscera Biosciencies, Santa
Clara, CA, USA) according to the manufacturer’s instructions. A microwell plate was coated with 100 μl of capture
antibody (1 µg/ml) against ESM-1, incubated overnight at
4°C, and then coated again with 1% BSA. Then, 100 μl of
serially diluted ESM-1 standard solution included in the
ELISA kit, and samples diluted fivefold in dilution buffer
(2% BSA in PBST) were applied to wells in triplicate and
incubated with 0.25 μg/ml detection antibody for 1 h, at
room temperature. After washing the wells with PBST solution, 100 μl of diluted HRP-conjugated streptavidin was
applied to each well for 30 min. Subsequently, tetramethylbenzidine (TMB) solution was added to the wells, and
then the reaction was stopped with 1 N H2SO4 solution.
The absorbance was then measured at 450 nm on a MultiSkan microplate reader (Thermo).
Statistical analysis
For relative mRNA expression quantification, the
comparative CT method (2–ΔΔCT) was used, and expression
levels for each sample were normalized to the expression
level of the reference genes HPRT1 and β-Actin. qPCR
experiments were conducted in triplicate. A p<0.05 was
considered statistically significant. For single ESM-1 and
CXCL3 ELISA assays and for multi-analyte ELISA array,
data were reported as mean ± SEM. Statistical difference
in gene expression for ESM-1 and for each chemokine,
between PC-3 prostatic cancer cell line and the control
cell line, and between PC-3 cells transfected with ESM1-siRNA and PC-3 cells transfected with control-siRNA,
was calculated with the T-test using GraphPad Prism 5
software (GraphPad Software Inc, San Diego, CA); p<0.05
was considered statistically significant.
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RESULTS
ESM-1 and CXC chemokine expression in PC-3 prostate cancer cells
Transcript and protein expression data for ESM-1 and
CXC chemokines are presented in Figure 1. Overall, qPCR
results showed that, compared to non-tumorigenic PWR1E cells, metastatic PC-3 cells overexpressed transcripts
encoding ESM-1 and transcripts encoding the ELR+ CXC
chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6,
and CXCL8. Conversely, transcripts encoding the ELR−
CXC chemokines CXCL9, CXCL10, CXCL11, and
CXCL14 were not detected in either PC-3 or PWR-1E cells
(Figure 1A). At the protein level, ESM-1 ELISA assay confirmed the high expression level of ESM-1 in the supernatant of cultured PC-3 cells. ESM-1 was not detected in the
supernatant of the control non-tumorigenic PWR-1E cells.
Multiplex and single ELISA assays confirmed the differential CXC chemokine profiles between PC-3 cells and the
control non-tumorigenic PWR-1E cells. Culture medium
from PC-3 cells had high levels of ELR+ CXC chemokines
CXCL1, CXCL3, and CXCL8 but low levels of ELR- CXC
chemokines CXCL9 and CXCL10, and non- detected levels of CXCL11. In contrast, the non-tumorigenic PWR-1E
cells had low levels of both ELR+ and ELR- CXC chemokines (Figure 1B). These results are consistent with the
highly metastatic phenotype of PC-3 cells and the nontumorigenic phenotype of PWR-1E cells.
ESM-1 and CXC chemokine expression of siRNA
transfected PC-3 cells
ESM-1 and CXC-chemokine genes, which are implicated in invasion and migration, were analyzed at the
transcript and protein levels by qPCR and ELISA, respectively, in PC-3 cells transfected with either ESM-1-siRNA
or control-siRNA (Figure 2). As shown in Figure 2A, at
48 h post transfection, the transcript level of ESM-1 in
cells transfected with ESM-1 siRNA were significantly
reduced compared with cells transfected with control
siRNA. Knockdown of ESM-1 in PC-3 cells did not affect the transcript expression of most CXC chemokines,
except for CXCL3. PC-3 cells transfected with ESM-1
siRNA had significantly lower transcript levels of CXCL3
compared to PC-3 cells transfected with control-siRNA.
Decreased expression of CXCL3 was specific for ESM-1
siRNA transfected PC-3 cells since there was no significant difference in CXCL3 transcript expression in untransfected PC-3 cells compared to PC-3 cells transfected with
control-siRNA. CXCL7, CXCL9, CXCL10, CXCL11 and
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Figure 1. ESM-1 and CXC-chemokine expression in PC-3
cells relative to non-tumorigenic PWR-1E cells. A, Transcript
expression levels for ESM-1, ELR+ CXC chemokines (CXCL1,
CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8), and
ELR− CXC chemokines (CXCL4, CXCL9, CXCL10, CXCL11,
CXCL12, CXCL14), were analyzed in the cell lines by RTqPCR. Relative changes in gene expression for each target gene
were calculated using the comparative CT method (2–ΔΔCT) normalizing to the expression levels of reference genes (HPRT-1
and β-actin). Greater than twofold expression changes were
regarded as significant and are marked by asterisks; B, Protein
levels were measured using quantitative commercial enzymelinked immunosorbent assay/ELISA for ESM-1 and CXC chemokines, according to the manufacturer’s instructions. Chemokines evaluated were CXCL1/GROα, CXCL3, CXCL8/IL8,
CXCL9/MIG, CXCL10/ IP-10, and CXCL11/I-TAC. ESM-1 and
CXC chemokine levels in cell supernatants are shown as mean
± SEM.
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Figure 2. ESM-1 and CXC chemokine expression of siRNA
transfected PC-3 cells. A, At 48 h post transfection, transcript
level of ESM-1 in cells transfected with ESM-1 siRNA was significantly reduced compared with cells transfected with control siRNA. Knockdown of ESM-1 in PC-3 cells did not affect
the transcript expression of most CXC chemokines, except for
CXCL3. ESM-1 silencing was associated to decreased transcript
levels of CXCL3 chemokine, compared to cells transfected
with control siRNA or untransfected cells; B, Knockdown of
ESM-1 in PC-3 cells significantly reduced the ESM-1 protein
level and it was associated to decreased level of CXCL3. ESM-1
knockdown did not affect the protein expression of the remaining CXC chemokines evaluated. Chemokines evaluated were
CXCL1/GROα, CXCL3, CXCL8/IL8, CXCL9/MIG, CXCL10/
IP-10, and CXCL11/I-TAC. ESM-1 and CXC chemokine protein
levels in cell supernatants are shown as mean ± SEM. siControl:
PC-3 cells transfected with control siRNA.siESM-1: PC-3 cells
transfected with ESM-1 siRNA for 48 h.
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Effect of ESM-1 siRNA knockdown in migration of
PC-3 cells
A wound healing assay revealed that 48 h after scratch
treatment, the open wound area of ESM-1 siRNA-transfected cells was significantly larger compared to that of
control-siRNA-transfected or untransfected cells (Figure
4). Thus, knockdown of ESM-1 in PC-3 cells inhibited cell
migration in vitro.

DISCUSSION
Prostate cancer is the most frequently diagnosed nonskin cancer in the United States (24) and the incidence of
metastatic prostate cancer has increased in the last decade in this country (25). Increasing efforts have been addressed to understand the biology of this disease. Endocan
is a soluble proteoglycan that is overexpressed by metastatic cell lines from different origins, including prostate
(3, 4), glioblastoma (7), colon cancer (26), among others.
It has been also found circulating in the bloodstream of
healthy individuals, patients with inflammatory diseases
and cancer patients (9, 11, 27). Increasing evidence shows
the involvement of this proteoglycan in the control of
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nor the proliferation (Figure 3B), of PC-3 cells transfected
with ESM-1 siRNA were significantly different to that of
PC-3 cells transfected with control siRNA. Forty-eight
hours after transfection, cell viability and cell proliferation was 94.4% in ESM-1-siRNA transfected PC-3 cells
compared to PC-3 cells transfected with control-siRNA.
Thus, ESM-1 siRNA knockdown did not significantly affect cell proliferation of PC-3 cells.

fundamental cellular processes such as adhesion, migration and angiogenesis (28). Among these, angiogenesis is
central for cancer progression, and it is regulated by both
activator and inhibitor molecules, including endocan and
CXC chemokines, which are increasingly shown to play a
key role in angiogenesis of cancer (28, 29). So far, the role
of endocan in prostate cancer remains unknown.
In the present study we investigated whether siRNAmediated silencing of endocan expression affected proliferation, migration and/or CXC chemokine expression of
PC-3 cells. We found that siRNA-mediated silencing of
endocan expression in the highly metastatic prostate cancer cell line PC-3 results in decreased migration with no
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Figure 3. Cell viability and proliferation of siRNA transfected
PC-3 cells. Cell survival (A) and proliferation rate (B) of PC-3
cells transfected with siESM-1 or siControl, were analyzed 48
h post-transfection using a MTS-based colorimetric test and
direct cell counting trypan blue dye exclusion, respectively.
Knockdown of ESM-1 did not affect cell viability or proliferation of PC-3 cells. siControl: PC-3 cells transfected with control
siRNA. siESM-1: PC-3 cells transfected with ESM-1 siRNA.
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chemokine family and it is sub-classified as a Glu-LeuArg (ELR+) CXC chemokine (33). CXCL3 has been found
previously over-expressed in the aggressive PC-3 cell line
and its tissue expression correlates with prostate cancer
metastasis (32, 34). Our results show that ESM-1 targeting in PC-3 cells resulted in decreased migration, which
may be related, at least in part, to decreased expression of
the angiogenic CXCL3 chemokine whose expression was
found to be reduced in endocan siRNA transfected cells.
CXCL3 has been shown to act as a chemoattractant for
neutrophils to areas of brain injury (35) and for cerebellar progenitor cells (36), while it is not clear for prostate
cancer cells if this chemokine is chemoattractant or not
(32). The results shown here deserve further investigation.
Additional studies are required to determine the mechanisms underlying the decreased expression of CXCL3 in
endocan siRNA silenced PC-3 cells, and more research is
needed to ascertain the biological role of ESM-1 in prostate cancer. It will be important to determine the effects of
ESM-1 knockdown in other recognized angiogenic markers and the effects of ectopically expressing ESM-1 in cells
with ESM-1 knockdown.
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Figure 4. Cell migration of siRNA transfected PC-3 cells. Cell
migration of PC-3 cells was assayed with the scratch “wound
healing” assay. Knockdown of ESM-1 in PC-3 cells inhibited
migration in vitro. siControl: PC-3 cells transfected with control
siRNA. siESM-1: PC-3 cells transfected with ESM-1 siRNA.
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